- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Apollo Endosurgery Gets FDA Clearance for Polypropylene Suture-Anchor Assembly
Apollo Endosurgery (NASDAQ:APEN) has announced it has received 510(k) clearance from the US Food and Drug Administration for its polypropylene suture-anchor assembly for use with the overstitch endoscopic suturing systems. As quoted in the press release: This proprietary suture-anchor implant is used as part of Apollo’s OverStitch™ and OverStitch Sx™ Endoscopic Suturing Systems to pass …
Apollo Endosurgery (NASDAQ:APEN) has announced it has received 510(k) clearance from the US Food and Drug Administration for its polypropylene suture-anchor assembly for use with the overstitch endoscopic suturing systems.
As quoted in the press release:
This proprietary suture-anchor implant is used as part of Apollo’s OverStitch™ and OverStitch Sx™ Endoscopic Suturing Systems to pass and anchor suture in the gastrointestinal tract.
Apollo is currently distributing a suture anchor that is manufactured by a third party according to Apollo design specifications. “Obtaining 510(k) clearance for our own proprietary suture-anchor component is expected to improve our gross margins, and allow us greater control over the supply of our suture by reducing our dependency on third party suppliers. This will be key as we seek to expand into new OverStitch markets outside the United States,” stated Todd Newton, Apollo’s Chief Executive Officer.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.